Gallotannin suppresses calcium oxalate crystal binding and oxalate- induced oxidative stress in renal epithelial cells

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 4, 2012, Pages 539-544

  Lee, Hyo Jung ^a   Jeong, Soo Jin ^a   Park, Moon Nyeo ^a   Linnes, Michael ^b   Han, Hee Jeoung ^a   Kim, Jin Hyoung ^a   Lieske, John Charles ^b   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Calcium oxalate monohydrate; Gallotannin; Monocyte chemoattractant protein 1; Osteopontin; Reactive oxygen species; Renal epithelial cell

Indexed keywords

MALONALDEHYDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE SUBUNIT P22; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE SUBUNIT P47; OSTEOPONTIN; OXALIC ACID; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TANNIN; UNCLASSIFIED DRUG; WHEWELLITE;

ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; CELL ADHESION; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; CYTOTOXICITY TEST; DRUG STRUCTURE; ENZYME ACTIVITY; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KIDNEY EPITHELIUM; MONOCYTE CHEMOATTRACTANT PROTEIN 1 GENE; NEPHROLITHIASIS; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE SUBUNIT P22 GENE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE SUBUNIT P47 GENE; OSTEOPONTIN GENE; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CALCIUM OXALATE; CELL LINE; CELL SURVIVAL; CHEMOKINE CCL2; CRYSTALLIZATION; DOGS; EPITHELIAL CELLS; HUMANS; HYDROLYZABLE TANNINS; KIDNEY; KIDNEY CALCULI; MALONDIALDEHYDE; NADPH OXIDASE; OSTEOPONTIN; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SUPEROXIDE DISMUTASE;

EID: 84859469252     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.539     Document Type: Article

References (28)

1. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin. Exp. Nephrol., 8, 75-88 (2004).
2. Umekawa T, Tsuji H, Uemura H, Khan SR. Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU Int., 104, 115-120 (2009).
3. Itoh Y, Yasui T, Okada A, Tozawa K, Hayashi Y, Kohri K. Preventive effects of green tea on renal stone formation and the role of oxidative stress in nephrolithiasis. J. Urol., 173, 271-275 (2005).
4. Bashir S, Gilani AH. Antiurolithic effect of Bergenia ligulata rhizome: an explanation of the underlying mechanisms. J. Ethnopharmacol., 122, 106-116 (2009).
5. Lee HJ, Jeong SJ, Lee HJ, Lee EO, Bae H, Lieske JC, Kim SH. 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose reduces renal crystallization and oxidative stress in a hyperoxaluric rat model. Kidney Int., 79, 538-545 (2011).
6. Dörrenhaus A, Müller JI, Golka K, Jedrusik P, Schulze H, Föllmann W. Cultures of exfoliated epithelial cells from different locations of the human urinary tract and the renal tubular system. Arch. Toxicol., 74, 618-626 (2000).
7. Asplin JR, Parks JH, Chen MS, Lieske JC, Toback FG, Pillay SN, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int., 56, 1505-1516 (1999).
8. Meyer JL, Smith LH. Growth of calcium oxalate crystals. I. A model for urinary stone growth. Invest. Urol., 13, 31-35 (1975).
9. Lee JH, Yehl M, Ahn KS, Kim SH, Lieske JC. 1,2,3,4,6-Penta-O-galloyl- beta-D-glucose attenuates renal cell migration, hyaluronan expression, and crystal adhesion. Eur. J. Pharmacol., 606, 32-37 (2009).
10. Lieske JC, Leonard R, Toback FG. Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am. J. Physiol., 268, F604-F612 (1995).
11. Kleinman JG, Wesson JA, Hughes J. Osteopontin and calcium stone formation. Nephron Physiol., 98, 43-47 (2004).
12. Kumar V, Lieske JC. Protein regulation of intrarenal crystallization. Curr. Opin. Nephrol. Hypertens., 15, 374-380 (2006).
13. Peixoto EB, Pessoa BS, Biswas SK, Lopes de Faria JB. Antioxidant SOD mimetic prevents NADPH oxidase-induced oxidative stress and renal damage in the early stage of experimental diabetes and hypertension. Am. J. Nephrol., 29, 309-318 (2009).
14. Marengo SR, Romani AM. Oxalate in renal stone disease: the terminal metabolite that just won't go away. Nat. Clin. Pract. Nephrol., 4, 368-377 (2008).
15. Rashed T, Menon M, Thamilselvan S. Molecular mechanism of oxalate-induced free radical production and glutathione redox imbalance in renal epithelial cells: effect of antioxidants. Am. J. Nephrol., 24, 557-568 (2004).
16. Butterweck V, Khan SR. Herbal medicines in the management of urolithiasis: alternative or complementary? Planta Med., 75, 1095-1103 (2009).
17. Serrano J, Puupponen-Pimiä R, Dauer A, Aura AM, Saura-Calixto F. Tannins: current knowledge of food sources, intake, bioavailability and biological effects. Mol. Nutr. Food Res., 53 (Suppl. 2), S310-S329 (2009).
18. Hall PM. Nephrolithiasis: treatment, causes, and prevention. Cleve. Clin. J. Med., 76, 583-591 (2009).
19. Wendt-Nordahl G, Evan AP, Spahn M, Knoll T. Calcium oxalate stone formation. New pathogenetic aspects of an old disease. Urologe A, 47, 538, 540-544 (2008).
20. McMartin K. Are calcium oxalate crystals involved in the mechanism of acute renal failure in ethylene glycol poisoning? Clin. Toxicol. (Phila.), 47, 859-869 (2009).
21. Okamoto M, Kohjimoto Y, Iba A, Saji F, Hara I, Shigematsu T. Calcium oxalate crystal deposition in metabolic syndrome model rat kidneys. Int. J. Urol., 17, 996-1003 (2010).
22. Kleinman JG, Beshensky A, Worcester EM, Brown D. Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney. Kidney Int., 47, 1585-1596 (1995).
23. Miyajima J, Hayashi T, Saito K, Iida S, Matsuoka K. The Interaction between female sex hormone receptors and osteopontin in a rat hyperoxaluric model. Kurume Med. J., 57, 73-80 (2010).
24. Boonla C, Hunapathed C, Bovornpadungkitti S, Poonpirome K, Tungsanga K, Sampatanukul P, Tosukhowong P. Messenger RNA expression of monocyte chemoattractant protein-1 and interleukin-6 in stone-containing kidneys. BJU Int., 101, 1170-1177 (2008).
25. Thamilselvan S, Byer KJ, Hackett RL, Khan SR. Free radical scavengers, catalase and superoxide dismutase provide protection from oxalate-associated injury to LLC-PK1 and MDCK cells. J. Urol., 164, 224-229 (2000).
26. Thamilselvan S, Hackett RL, Khan SR. Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. J. Urol., 157, 1059-1063 (1997).
27. Thamilselvan V, Menon M, Thamilselvan S. Selective Rac1 inhibition protects renal tubular epithelial cells from oxalate-induced NADPH oxidase-mediated oxidative cell injury, Urol. Res. (2011) [Epub ahead of print].
28. Selvam R. Calcium oxalate stone disease: role of lipid peroxidation and antioxidants. Urol. Res., 30, 35-47 (2002).